Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

IF 6.1 1区医学 Q1 ONCOLOGY

Breast Cancer Research Pub Date : 2017-02-09 DOI:10.1186/s13058-017-0806-9

G. Bianchini, A. Kiermaier, G. Bianchi, Y. Im, T. Pieńkowski, Mei-Ching Liu, L. Tseng, M. Dowsett, L. Zabaglo, S. Kirk, T. Szado, J. Eng-Wong, L. Amler, P. Valagussa, L. Gianni

引用次数: 83

查看原文本刊更多论文

NeoSphere研究的生物标志物分析:帕妥珠单抗、曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛、帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于her2阳性乳腺癌的新辅助治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research 医学-肿瘤学

自引率

0.00%

发文量

期刊介绍： Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.